CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|April 1, 2008
Drug Watch: Agents in late-stage development for the treatment of selected neurodegenerative disorders (April 2008) (PDF)
Drugs in development for the treatment of Huntington disease, Parkinson disease, and amyotrophic lateral sclerosis
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.
The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.
In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.
The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
2
McKesson, private equity firm buy home infusion company, Option Care Health
3
Medicare Advantage needs fixing. Here are 3 feasible repairs
4
Christine Johnston on why biosimilars are losing formulary ground
5